PANACEABIOPANACEABIO Forensic Risk Analysis

Pharmaceuticals
Risk ClassWatch
Market CapN/A
Primary DriverBalance Sheet Stress
Flagium AI Risk Score
Early signs of stress detected. Not yet widespread, but initial deterioration is visible.
25 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in balance sheet stress. This suggests the risk profile is currently stabilizing. Risk levels are improving.

65.7th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹430.6▲8.18%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress
+10.6 pts
Stability Adjustment
+14.0 pts
Final Composite Risk25 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 13 → 25 over 13 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Inventory Stress
  • Industrial Margin Stress
  • Relative Growth Weakness
What to Watch Next Quarter
  • Working capital efficiency
  • Operating profit margins
  • Debt growth

Active Risk Objects (10)

CriticalHigh
Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ2 FY2026
Working capital expansion detected: Receivable days increased by 24.6%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Industrial Margin Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight12/15
MomentumDecaying
Last SignalQ4 FY2025
PANACEABIO: EBITDA margin compressed by 16.4 bps YoY and Raw material costs consumed an additional 28.1% of revenue YoY.

"Operating efficiency is stabilizing. The rate of margin deterioration has slowed."

Low Interest Coverage
💧 Liquidity & CoverageQuarterlyActive for 7 Qtrs
More Detail
Impact Weight8/15
MomentumPersistent
Last SignalQ4 FY2026
PANACEABIO: Low Interest Coverage Ratio of -0.04x in FY2026 Q4 (Threshold: 2.5x).

"Interest coverage is dangerously low. Even a minor fall in profit could trigger a default."

Operating Leverage Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ3 FY2026
Expenses are consistently growing faster than revenues, creating operational pressure.

"The balance sheet is heavily over-leveraged. Interest payments are consuming most of the profit."

Profit Collapse
📊 Earnings QualityQuarterlyActive for 4 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ2 FY2026
PANACEABIO: Net Profit collapsed by 397.5% from FY2025 Q2 to FY2026 Q2.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Negative FCF Streak
⚖️ Governance SignalsAnnualActive for 3 Years
More Detail
Impact Weight6/15
MomentumPersistent
Last SignalFY2026
PANACEABIO: Negative Free Cash Flow for last 3 consecutive years.

"High capital expenditure and low OCF are draining cash. Debt levels may rise sharply."

Relative Growth Weakness
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight12/15
MomentumDecaying
Last SignalQ4 FY2025
Revenue growth consistently lags behind sector median (12.8%).

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumDecaying
Last SignalQ4 FY2025
Inventory growth (20.1%) significantly outpaced revenue growth (-4.2%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Cash Conversion Deficit
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight6/15
MomentumDecaying
Last SignalFY2025
PANACEABIO: OCF below Net Profit in 2/3 recent years.

"Cash conversion has normalized in the latest period. Operational cash flow is back in sync."

Revenue-Debt Divergence
🏛️ Solvency & LeverageAnnualActive for 1 Years
More Detail
Impact Weight6/15
MomentumDecaying
Last SignalFY2025
PANACEABIO: Revenue fell 0.9% while Debt rose 5.8% in 2025 vs 2024.

"Debt servicing metrics have improved recently. The company is actively deleveraging."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)97.70⚠️ HIGH
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+41.0+47.0📈 CRITICAL
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹430.6(+8.18%)
1M Divergence+17%
1 Week+1.54%
1 Month+19.26%
6 Months+24.02%
1 Year-14.56%
2 Year+228.7%
3 Year+257.2%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The risk profile is Early Signals and currently improving. Recent structural triggers in balance sheet stress suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Initial structural recovery is visible; monitor for a sustained return to resilience.

PANACEABIO • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.9%
Trend QualityEarly Base
Phase Progression
Phase Progression Score40%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing9%
CoinTree Momentum
Composite Z-Score+0.8641σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#286 of 2716
Top 10.53% in momentum strength
Timeframe Sparklines
1W+1.5%
1M+19.3%
6M+24.0%
Weinstein Indicators
150 DMA₹368.76
200 DMA₹381.84
150 DMA Slope-0.8847%Declining
Relative Strength+29.51%Leading
Relative Turnover (RTR)0.3730
ParticipationWeak

PEER COMPARISON

Ranked comparison against sector peers

This company shows higher risk compared to the Sector Mean (19).
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

PANACEABIOPANACEABIO
25 Risk
Sector %ile66th
Delta-5
Active Flags10
Accel+0
Balance Sheet Stress

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

BALAXIBALAXI PHARMACEUTICALS LIMITED
45 Risk
Sector %ile96th
Delta+10
Active Flags40
Accel+1
Balance Sheet Stress

Moderate Deterioration

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
4.747.2th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Operating Leverage Stress

2026

Working Capital Expansion

2026

Negative FCF Streak

2025

Industrial Margin Stress

2025

Relative Growth Weakness

2025

Working Capital Expansion

2025

Inventory Stress

2025

Relative Growth Weakness

2025

Cash Conversion Deficit

2025

Revenue-Debt Divergence

2025

Negative FCF Streak

2024

Industrial Margin Stress

2024

Negative FCF Streak

2024

Cash Conversion Deficit

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY2026657-71724
FY2025580-9-2722
FY2024585-2-021
FY2023512-34-42320